Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Generics Bulletin Originals

Set Alert for Originals
What's Next?

What’s Next? Five Things To Look Out For In January

The biggest loss of exclusivity in pharmaceutical history is set to steal headlines in the first month of 2023, as Teva begins a new year with a new CEO.

Biosimilars Generic Drugs

What’s Next? Five Things To Look Out For In December

In a busy final month of the year, key legal action will be heard in both the US and Europe, while the Medicines Patent Pool will hear from applicants for a milestone voluntary licensing agreement covering Novartis’ nilotinib.

Biosimilars Generic Drugs

What’s Next? Five Things To Look Out For In November

European litigation, potential US generic launches and new CEOs are among the headlines in November – amid the ninth annual Global Generics & Biosimilars Awards, in Frankfurt.

Biosimilars Generic Drugs

What’s Next? Five Things To Look Out For In October

A busy October will include planned biosimilar launches and key appointments for the off-patent sector.

Generic Drugs Biosimilars
See All
Interviews

Dr Reddy’s CEO Sees Strength Through Diversity

With Dr Reddy’s organization now spanning a range of innovative interests and CDMO activities as well as the firm’s traditional small-molecule generics and burgeoning biosimilars businesses, CEO Erez Israeli talked to Generics Bulletin about how these various areas were complementary thanks to the Indian giant’s ‘two-horizon’ approach.

Strategy Generic Drugs

Fresenius Kabi: Adalimumab Customers Want Supply Guarantee, We Can Provide That

Following Fresenius Kabi’s approval in mid-December for the eighth and latest biosimilar Humira (adalimumab) product, the company’s senior vice president for biosimilars in the US spoke to Generics Bulletin about how it can stand out from the pack and why it is confident that it can succeed.

Biosimilars Manufacturing

Biogen: Patients Must Be At Center Of UK Biosimilar Decision Making

The head of biosimilars for Biogen in the UK & Ireland, Jim Porter, sat down with Generics Bulletin to discuss “system challenges and changes that we’re seeing within the UK’s NHS,” as well as Biogen’s own position in what it says is a very important market for the company.

Biosimilars Supply Chain

Regulatory Reform Could Elevate Value-Added Medicines To Their ‘Rightful Place’, Says Narayan

Medicines for Europe is calling on the EU to recognize value-added medicines as its own separate group in its pharmaceutical legislation.

Value-Added Medicines Regulation
See All
Pricewatch UK

UK Prices Double For Multiple Molecules In December

Average trade prices for multiple products more than doubled in December in the UK, according to the latest figures from market researcher WaveData.

Market Intelligence Pricing Strategies

UK Prices See A Raft Of Rises In November

Multiple treble-digit price rises were seen for UK generics in November as a lengthy list of price concessions was issued by the Department of Health and Social Care.

Market Intelligence Pricing Strategies

Aripiprazole Returns To Lead October Rises In UK

Having led the fastest-rising average trade prices in the UK in August, aripiprazole once again topped our table of Biggest Risers in October, based on the latest figures from market researcher WaveData – but this time it was the oral solution presentation of the product that saw a spike.

Market Intelligence Pricing Strategies

Prices Double For Multiple UK Generics In September

September brought triple-digit percentage increases in the average trade price of multiple UK generics, according to the latest figures from WaveData.

Market Intelligence Pricing Strategies
See All
UsernamePublicRestriction

Register